PRACTICAL IMPLICATIONS OF SPONTANEOUS ADVERSE DRUG REACTION REPORTING SYSTEM IN HOSPITALS-AN OVERVIEW
Adverse drug reactions (ADRs) are global problems of major concern which leads to morbidity and mortality. It causes 30 of hospitalized patients and lead 2-6 of all medical admissions. Spontaneous reporting of ADRs is the cornerstone of pharmacovigilance and is essential for maintaining patient safety. The necessity of a spontaneous ADR surveillance system is addressed by many authorities like World Health Organization, Food and Drug Administration, Joint Commission International and Uppsala monitoring center. However, existing postmarketing surveillance systems massively rely on spontaneous reports of ADRs which suffer from serious underreporting, latency, and inconsistent reporting. Studies estimated that only 6â€“10 of all ADRs are reported in hospitals. It is a very low percentage to go in deep and analyze the reason for the same and to resolve that underlying factors. Researchers proved that knowledge, attitude and false perceptions about the ADRs are the major challenges in the spontaneous reporting of ADRs. Which includes personal, professional, system related and organization related conflicts. Majority of them can improve by doing the system and personal targeted implications. Identifying, analyzing and working on these issues can improve the ADR surveillance system in hospitals to attain the patient safety. Understanding the pharmacovigilance, identifying and sorting out the obstacles of spontaneous reporting through an efficient pharmacovigilance department, continuous educational interventions, patient centered surveillance programs, health care team work efforts towards the detection of ADRs and implementation of the computer or personal assisted ADR trigger tool programs can furnish out a successful pharmacovigilance system in the hospitals and thereby we can constitute a good quality health care system.
Key words: Spontaneous reporting system, adverse drug reaction, pharmacovigilance, Patient safety
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tregeder I, Schneider HT, Hahn EG, Levy M, Brune K, Gresslinger G. Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000, 22:161â€“8.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004, 329:15-19.
Oshikoya KA. Adverse drug reaction in children: types, incidence and risk factors. Nig J Paediatr 2006, 33:29-35.
Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993, 27:832â€“40.
Classen DC, Pestotnik SL, Scott Evans R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. JAMA 1997;277:301â€“306
Levy M, Kewitz H, Altwein W, Hillerbrand J, Eliakim M. Hosptial admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17:25â€“31.
Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008, 42:1017-1025.
Moore N, Lecointre D, Noblet C, Mabille M: Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45:301-8.
Kohn LT, Corrigan JM, Donaldson MS, eds. Institute of Medicine Report: To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, November 29, 1999, Available At: http://bob.nap.edu/html/to_err_is_human/.
Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277:307â€“311
Ayani I, Aguirre C, Gutierrez G, Madariaga A, RodrÃguez-SasiaÃn JM, MartÃnez-Bengoechea MJ: A cost analysis of suspected adverse drug reactions in a hospital emergency ward. Pharmacoepidemiol Drug Saf 1999, 8:529-534.
Wu WK, Pantaleo N: Evaluation of outpatient adverse drug reactions leading to hospitalization. Am J Health Syst Pharm 2003, 60:253-259.
International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; 426:5â€“24.
Pearson KC, Kennedy DL: Adverse drug reactions and the Food and Drug Administration. J Pharm Pract 1989; 2:209â€“13.
Joint Commission on Accreditation of Healthcare Organizations: Accreditation Manual for Hospitals, 1991. Chicago, IL: Joint Commission on Accreditation of Healthcare Organizations, 1991
WHO: Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre, [http://www.who.int/medicinedocs]. Accessed May 16, 2005.
Cluff LE, Caranasos GJ, Stewart RB. Clinical problems with drugs. In: Smith LH, ed. Major problems in internal medicine. Philadelphia, PA: WB Saunders, 1975:5.
Ralph Edwards: Spontaneous reportingâ€”of what? Clinical concerns about drugs. Br J Clin Pharmacol 1999; 48, 138â€“141
Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond 1995; 29: 41â€“49
Barbara Kozamernik. Spontaneous adverse drug reaction reporting: attitudes and practice of health care professionals and distributors in South East European region. farm vestn 2010; 61
Chetna K. Desai, Geetha Iyer, Jigar Panchal, Samidh Shah, and R. K. Dikshit, An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res 2011 Oct-Dec; 2(4): 129â€“136.
Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Safety 1997; 16: 355â€“365.
Lexchin J: Is there a role for spontaneous reporting of adverse drug reactions? CMAJ 2006, 174:191-192.
Lopez-Gonzalez E, Herdeiro MT, Figueiras A: Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009, 32:19-31.
Fletcher A. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991; 84:341-4.
Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG: Adverse drug reaction in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996, 42:423-429.
Feely J, Moriarty S, O'Connor P: Stimulating reporting of adverse drug reaction by using a fee. Br Med J 1990, 300:22-23.
Herdeiro MT, Figueiras A, PolÃ³nia J, Gestal-Otero JJ. Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2006; 29(4):331-40.
Inman WH: Attitudes to adverse drug-reaction reporting. Br J Clin Pharmacol 1996, 41:433-435.
A. Vallano,, G. Cereza,C. PedrÃ²s,, A. AgustÃ,, I. DanÃ©s,, C. Aguilera,& J. M. Arnau. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005; 60:6: 653-8
Kelly M, Kaye KI, Davis SR, et al. 2004. Factors influencing adverse drug reaction reporting in New South Wales teaching hospitals. J Pharm Pract Res, 34:32â€“5.
Christopher F. Green,1 David R. Mottram,1 Philip H. Rowe1, Munir Pirmohamed. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol, 51, 81-86
Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf. 2000 Aug;23(2):165-72.
Kazeem A Oshikoya and Jacob O Awobusuyi. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clinical Pharmacology 2009, 9:14
Desai CK, Iyer G, PanchalJ, Shah S, Dilkshit RK. An evaluation of knowlwdge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res 2011 oct;2(4):129-36.
Monica Zolezzi and Nirasha Parsotam, Adverse drug reaction reporting in New Zealand: implications for pharmacists, Ther Clin Risk Manag. 2005 September; 1(3): 181â€“188.
Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27:519-34.
Erice Report. Effective communications in pharmacovigilance, published by The Uppsala Monitoring Centre, Uppsala, Sweden 1997
Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ: An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA 2006, 296:1086-1093.
Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA: A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Br J Clin Pharmacol 2005, 60:221-223.
Khalili H, Mohebbi N, Hendoiee N, Keshtkar AA, Khavidaki SD. Improvement of knowledge, attitude and perception of healthcare workers about ADR, a pre- and post clinical pharmacists intervention study: BMJ Open 2012;2:e000367.
Manuela Tabali, Elke Jeschke, Angelina Bockelbrink, Claudia M Witt, Stefan N Willich, Thomas Ostermann and Harald Matthes,. Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health 2009, 9:274
Michel DJ, Knodel LC. Program coordinated by a drug information service to improve adverse drug reaction in a hospital. Am J Hosp Pharm. 1986;43:2202â€“2205
[ASHP] American Society of Health-System Pharmacists. 1995. Guidelines on adverse drug reaction monitoring and reporting [online]. Accessed Nov 2004. URL: www.ashp.org/bestpractices/MedMis/ MedMis_Gdl_ADR.pdf.
Uppsala Monitoring Center, WHO Collaborating Centre for International Drug Monitoring. 2000. Safety monitoring of medicinal products. Guidelines for setting up and running a pharmacovigilance centre. Uppsala: Uppsala Monitoring Center.
Hassali M, Kong D, Stewart K. Knowledge and perceptions of recent pharmacy graduates about generic medicines. Pharm Educ. 2007; 7(1):89.
Sainul Abideen P, Chandrasekaran K, Uma Maheswaran, Vijayakumar A, Kalaiselvan V, Pradeep Mishra, Moza Al Hail, Abdul Rouf, Binny Thomas. Implementation of Self Reporting Pharmacovigilance in Anti Tubercular Therapy Using Knowledge Based Approach. J Pharmacovigilance 2013, 1(1): 1-5
Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A (2002) Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 53: 318-325.
Krska J, Jarernsiripornkul N, Capps PAG, Richards. Patients self reports of potential adverse drug reactions. Int J Pharm Pract 2001; R35.
Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266(20):2847-51
J D Rozich, C R Haraden, R K Resar. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care 2003;12:194â€“200
Steven M. Handler, Subashan Perera, Yazan F. Roumani, David A. Nace, Douglas B. Fridsma, Melissa I. Saul, Nicholas G. Castle, and Stephanie A. Studenski. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J Am Geriatr Soc. 2008; 56(5):808-815.
All trigger tools for measuring ADEs. Institute for healthcare improvement (IHI). Available at app.ihi.org/workspace/tools/trigger/alltools.aspx
American Society of Health-System Pharmacists. Top-priority actions for preventing adverse drug events in hospitals. Recommendations of an expert panel. Am J Health-Syst Pharm. 1996; 53:747-751.
Brenner S, Detz A, Lopez A, Horton C, Sarkar U. Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Qual Saf. 2012 Aug:21(8):670-5.
Mull HJ, Nebeker JR, Shimada SL, Kaafarani HM, Rivard PE, Rosen AK. Consensus building for development of outpatient adverse drug event triggers. J Patient Saf 2011 Jun;7(2):66-71
Matlow AG, Cronin CM, Flintoft V, Nijssen-Jordan C, Fleming M, Brady-Fryer B, Hiltz MA, Orrbine E, Baker GR. Description of the development validation of the Canadian paediatric trigger tool. BMJ Qual Saf 2011 May; 20(5):416-23.
Seddon ME, Jackson A, Cameron C, Young ML, Escott L, Maharaj A, Miller N. The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. N Z Med J. 2012 Jan 25; 126(1368):9-20.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.